Roche loses patent opposition in India
10 May 2010
Peter Ollier, Hong Kong
In another blow to multinational pharmaceutical companies in India, the Chennai Patent Office has invalidated a key patent owned by Swiss drug maker F Hoffmann La Roche, allowing generic competitors to enter the market
In the May 5 decision, S P Subramanian, the assistant controller of patents and designs, said that the patent covering Valcyte (valganciclovir hydrochloride) lacks inventive step and does not demonstrate significantly improved efficacy over previous compounds, as required by India's Patent Law.
Valcyte is used to prevent infection in people who have undergone organ transplants and in people who suffer from HIV and AIDS.
"This decision raises the huge question of how credible is a patent grant in India - should the courts take a presumption of validity or not?" said Abhai Pandey, of Lex Orbis in New Delhi.
The Chennai Patent Office published
patent (no 207232)
on June 29 2007. Six parties, including Indian generics companies Ranbaxy and Cipla and two organisations campaigning for the rights of people with HIV and AIDS, filed a...
Only subscribers have complete access to Managing IP Magazine,
log in or
subscribe now.
Alternatively take a
free trial, giving you 48-hour access to Managing IP Magazine (some articles and surveys may be excluded).
Subscribe Now
This article is available to subscribers. Please click subscribe to read the rest of the article.
Subscribe
Take a free trial
Please take a free 48-hour trial to gain limited access. Some articles and surveys may be excluded.
Take a free trial